V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005457 | 10003409 | 1.7 | 43 | Adjuvant (A) | null | 2017-01-06 | Cyclophosphamide + Docetaxel | N | N | 10490112 | CAPECITABINE + CISPLATIN + RT |
| 10005458 | 10003410 | 1.6 | 86.5 | Neo-adjuvant (N) | 2017-12-09 | 2018-01-04 | RUXOLITINIB | N | Y | 10491171 | CAPECITABINE + CARBOPLATIN |
| 10005459 | 10003411 | 1.67 | 81.5 | null | 2016-04-17 | 2016-04-20 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | 10491733 | IBRUTINIB |
| 10005460 | 10003412 | 1.67 | 60.9 | Disease modification (D) | 2014-05-30 | 2014-06-11 | R Chlorambucil | 02 | N | 10491830 | CAP + RT |
| 10005461 | 10006870 | 1.86 | 79 | Palliative (P) | 2019-03-04 | 2019-03-04 | BORTEZOMIB + THALIDOMIDE | 02 | null | 10492985 | CRIZOTINIB |
| 10005462 | 10006870 | 1.66 | 64.1 | Disease modification (D) | 2017-07-04 | 2017-07-09 | DABRAFENIB + TRAMETINIB | N | N | 10492985 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005463 | 10006870 | null | 81.5 | Palliative (P) | 2019-01-23 | 2019-01-23 | GEMCITABINE + NAB PACLITAXEL | N | null | 10492985 | DOXORUBICIN |
| 10005464 | 10006870 | null | null | Curative (C) | 2019-03-18 | 2019-03-19 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 10492985 | TRASTUZUMAB |
| 10005465 | 10003413 | 1.44 | 90 | Palliative (P) | 2019-11-10 | 2019-11-10 | Capecitabine (21days) + Carboplatin | 02 | N | 10501999 | BEVACIZUMAB |
| 10005466 | 10006871 | 1.54 | null | Curative (C) | 2016-10-23 | 2016-11-05 | Ipilimumab | N | N | 10502438 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10005467 | 10006871 | 1.66 | 0 | Radical (R) | 2018-07-23 | 2018-07-31 | MITOMYCIN | N | N | 10502438 | LOMUSTINE |
| 10005468 | 10006871 | 1.77 | 87 | Neo-adjuvant (N) | 2018-09-11 | 2018-10-05 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | N | N | 10502438 | IDELALISIB + RITUXIMAB |
| 10005469 | 10003414 | null | 70 | Palliative (P) | 2017-03-31 | 2017-03-31 | Erlotinib | 02 | N | 10504936 | ERLOTINIB |
| 10005470 | 10003415 | 1.72 | 95.2 | Palliative (P) | 2018-12-23 | 2018-12-23 | CISPLATIN + VINORELBINE + RT | 2 | N | 10505211 | BEVACIZUMAB |
| 10005471 | 10003416 | 1.78 | 100.7 | Disease modification (D) | 2018-12-08 | 2018-12-31 | MELPHALAN | 02 | Y | 10506342 | CETUXIMAB + IRINOTECAN + MDG |
| 10005472 | 10003416 | 1.77 | 81 | Palliative (P) | 2017-05-10 | 2017-05-17 | Sorafenib | N | N | 10506342 | SUNITINIB |
| 10005473 | 10003417 | 0 | 76.6 | Palliative (P) | 2018-12-10 | 2018-12-23 | Bendamustine +/- Prednisolone | 02 | N | 10507092 | SUNITINIB |
| 10005474 | 10003418 | 1.65 | null | Neo-adjuvant (N) | 2016-11-14 | 2016-11-16 | CLADRIBINE | 02 | N | 10507167 | IPILIMUMAB + NIVOLUMAB |
| 10005475 | 10003419 | 0 | 81.9 | Curative (C) | 2018-05-17 | 2018-06-07 | MPV (cycle 1-4) | N | N | 10507543 | MITOMYCIN INTRAVESICULAR |
| 10005476 | 10003420 | 0 | 76.65 | null | 2016-10-10 | 2016-10-12 | Pemetrexed | 01 | N | 10507575 | VISMODEGIB |
| 10005477 | 10003421 | null | 87.2 | Curative (C) | 2019-07-15 | 2019-07-19 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 2 | N | 10507805 | CYTARABINE |
| 10005478 | 10003422 | 1.63 | 91.4 | Palliative (P) | 2019-04-09 | 2019-04-15 | DABRAFENIB | Y | N | 10509594 | TRASTUZUMAB |
| 10005479 | 10003423 | 1.74 | 89 | Disease modification (D) | 2015-07-14 | 2015-07-21 | R GDP + DEXAMETHASONE | Y | N | 10510031 | BORTEZOMIB + THALIDOMIDE |
| 10005480 | 10003424 | null | 61.8 | Disease modification (D) | 2014-08-23 | 2014-08-26 | Cyclophosphamide + Docetaxel | 2 | null | 10510549 | EC + PACLITAXEL |
| 10005481 | 10003425 | 1.6 | 81.7 | Palliative (P) | 2015-09-04 | 2017-09-04 | Cetuximab + Irinotecan (Cycle 1) | 02 | N | 10510766 | CHLVPP |
| 10005482 | 10003426 | 1.56 | 49.4 | Adjuvant (A) | 2017-08-16 | 2017-08-16 | BORTEZOMIB + THALIDOMIDE | N | N | 10510971 | AFATINIB |
| 10005483 | 10003427 | 1.67 | 62 | Curative (C) | 2017-08-07 | 2017-08-29 | DA | 1 | N | 10511472 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10005484 | 10003428 | 1.77 | 81.7 | Adjuvant (A) | 2018-03-01 | 2018-03-01 | PERM Trial | 2 | N | 10512118 | MITOMYCIN INTRAVESICULAR |
| 10005485 | 10003429 | 1.62 | 63 | Curative (C) | 2017-01-16 | 2017-01-17 | Cyclophosphamide + Docetaxel | 02 | N | 10512238 | NOT MATCHED |
| 10005486 | 10003430 | 1.56 | null | Disease modification (D) | 2018-06-22 | 2018-06-27 | Capecitabine + Cisplatin + RT | 2 | N | 10512326 | FLUOROURACIL + MITOMYCIN |
| 10005487 | 10003431 | 1.75 | 60.2 | Palliative (P) | 2017-04-30 | 2017-04-30 | Cetuximab 7 day (Cycle 1) | N | N | 10512669 | RAVVA TRIAL |
| 10005488 | 10003432 | 1.76 | 71.1 | Curative (C) | 2017-06-26 | 2017-06-26 | CISPLATIN + FLUOROURACIL | N | N | 10513232 | MITOMYCIN INTRAVESICULAR |
| 10005489 | 10003433 | 1.71 | 0 | Palliative (P) | 2018-07-05 | 2018-07-17 | CYCLO + ETOPOSIDE + VINCRISTINE | N | N | 10513388 | EOF |
| 10005490 | 10003434 | 1.62 | 65.5 | Curative (C) | 2018-09-17 | 2018-09-18 | RUXOLITINIB | 02 | N | 10513607 | CETUXIMAB + IRINOTECAN + MDG |
| 10005491 | 10003434 | 1.67 | 93 | Curative (C) | 2018-04-10 | 2018-04-29 | Brentuximab | Y | null | 10513607 | IBRUTINIB |
| 10005492 | 10003434 | 1.53 | 41.1 | Curative (C) | 2018-03-27 | 2018-04-07 | ECF | 2 | N | 10513607 | DABRAFENIB |
| 10005493 | 10003434 | 1.72 | 70 | Palliative (P) | 2017-08-15 | 2017-08-28 | Pazopanib | N | N | 10513607 | CISPLATIN + FLUOROURACIL |
| 10005494 | 10003434 | null | 82.4 | Palliative (P) | 2017-02-14 | 2017-02-14 | EOF | 2 | N | 10513607 | MPV |
| 10005495 | 10003435 | 1.69 | 72 | null | 2017-03-19 | 2017-03-23 | AFATINIB | Y | N | 10514099 | AML18 TRIAL |
| 10005496 | 10006874 | 1.94 | 93.8 | Disease modification (D) | 2019-10-10 | 2019-10-19 | Cladribine (subcut) 5 days | 2 | N | 10514154 | PERM TRIAL |
| 10005497 | 10006874 | 0 | 77.5 | Palliative (P) | 2016-12-13 | 2016-12-13 | CYCLOPHOSPHAMIDE + PACLITAXEL | N | N | 10514154 | CAPECITABINE + MITOMYCIN + RT |
| 10005498 | 10003436 | null | 69.9 | Neo-adjuvant (N) | 2018-09-21 | 2018-09-24 | Ralitrexed | 02 | null | 10514905 | PAZOPANIB |
| 10005499 | 10003437 | 1.65 | null | null | 2016-08-26 | 2016-09-09 | PAM x 2 post-surgery (cycles 3&4) | 02 | N | 10515105 | CETUXIMAB + IRINOTECAN + MDG |
| 10005500 | 10003438 | 1.66 | 94.6 | Palliative (P) | 2018-12-09 | 2018-12-17 | R Chlorambucil | Y | N | 10515233 | MITOMYCIN INTRAVESICULAR |
| 10005501 | 10003439 | 1.68 | 56.8 | null | 2018-06-10 | 2018-07-08 | Docetaxel + Nintedanib | 2 | N | 10515836 | IBRUTINIB |
| 10005502 | 10003440 | 1.72 | 84 | Palliative (P) | 2019-06-08 | 2019-06-08 | HCX (Cape + Cisp + Tras) - Main | N | N | 10516553 | NOT MATCHED |
| 10005503 | 10003440 | 1.6 | 91.1 | null | 2017-06-06 | 2017-06-24 | Cisplatin + Docetaxel +Fluorouracil | N | Y | 10516553 | MELPHALAN |
| 10005504 | 10003441 | 1.7 | 59.9 | Disease modification (D) | 2019-01-10 | 2019-03-22 | Mitomycin Intravesical | 2 | N | 10519298 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10005505 | 10003441 | 1.75 | 57 | null | 2018-02-18 | 2018-02-25 | Bendamustine +/- Prednisolone | N | N | 10519298 | CAPECITABINE + CARBOPLATIN |
| 10005506 | 10003442 | 1.69 | 68 | Adjuvant (A) | 2018-07-06 | 2018-07-07 | Cape+Cisplatin+Trastuzumab Load | 2 | N | 10519538 | RUXOLITINIB |